The reality of the offer to purchase OCAT $8.50 is no less real than the higher worth of OCAT seen from a "true shareholders" perspective. The reason the first offer to purchase OCAT was turned down by shareholders leaves room for thought. If $8.50 is not good enough, what factors go in to finding the true value? How much could OCAT bring in with it's multi layered patented science with eyes/blood/tuffs etc. ?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.